Athira Pharma, Inc.
NASDAQ Global SelectTotal Valuation
Athira Pharma, Inc. carries a market capitalization of 26.62M, placing it among publicly traded companies globally. Its enterprise value stands at -8.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 26.62M |
| Enterprise Value | -8.09M |
Share Statistics
Athira Pharma, Inc. currently has 3.94M shares outstanding.
| Shares Outstanding | 3.94M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.04 |
| P/TBV Ratio | 0.61 |
| P/FCF Ratio | -0.31 |
| P/OCF Ratio | -0.31 |
Financial Position
Athira Pharma, Inc. maintains a current ratio of 9.70, meaning it holds 9.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.70 |
| Quick Ratio | 9.05 |
| Debt / Equity | 3.40 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -64.88 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Athira Pharma, Inc.'s stock has gained approximately 53.06122% over the past 52 weeks. The 50-day moving average sits at 5.48, while the 200-day moving average is 4.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | 53.06122% |
| 50-Day Moving Average | 5.48 |
| 200-Day Moving Average | 4.03 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -38.29M, while operating income came in at -39.27M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -39.27M |
| Pretax Income | -37.72M |
| Net Income | -37.72M |
| EBITDA | -38.29M |
| EBIT | -39.27M |
| Earnings Per Share (EPS) | -9.63 |
Balance Sheet
Athira Pharma, Inc. holds 25.23M in cash and equivalents against 912,000.00 in total debt, resulting in a net debt position of -20.87M. Total book value stands at -428.86M, with working capital of 24.24M providing operational flexibility.
| Cash & Cash Equivalents | 25.23M |
| Total Debt | 912,000.00 |
| Net Debt | -20.87M |
| Equity (Book Value) | -428.86M |
| Book Value Per Share | -109.43 |
| Working Capital | 24.24M |
Cash Flow
Athira Pharma, Inc. produced -52.34M in operating cash flow over the past twelve months.
| Operating Cash Flow | -52.34M |
| Capital Expenditures | N/A |
| Free Cash Flow | -52.34M |
| FCF Per Share | -13.36 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.36 |
| FCF Yield | -322.61 |
Stock Splits
Athira Pharma, Inc.'s most recent stock split took place on September 18, 2025 with a 10:1 split ratio.
| Last Split Date | 9/18/2025 |
| Split Ratio | 10:1 |
Scores
Athira Pharma, Inc. posts an Altman Z-Score of -20.34, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -20.34 |